GlassScriptPhysician profile
James F Schaupp
NPI 1770679706
$7,925.95
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,355 · 2020: $1,496 · 2021: $1,807 · 2022: $1,389 · 2023: $1,497 · 2024: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.22 |
| Education | $253.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $878.48 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Astellas Pharma US INC | $790.68 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $740.56 | 2019-2024 | Shingrix, Bexsero, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $730.19 | 2019-2023 | Farxiga |
| Pfizer INC. | $579.43 | 2019-2023 | |
| Amarin Pharma, INC. | $515.02 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.66 | 2019-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $349.42 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $263.43 | 2019-2023 | Gardasil 9, M-M-R II, Pneumovax 23 |
| Bayer Healthcare Pharmaceuticals INC. | $215.31 | 2021-2023 | |
| Allergan, INC. | $170.48 | 2019-2020 | |
| Lilly USA, LLC | $169.64 | 2020-2024 | Zepbound, Jardiance |
| Kowa Pharmaceuticals America, INC. | $167.62 | 2020-2022 | |
| Novo Nordisk INC | $158.01 | 2019-2023 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $131.91 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Schaupp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.